Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EBITDA (2016 - 2025)

Historic EBITDA for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$35.9 million.

  • Cartesian Therapeutics' EBITDA fell 4840.9% to -$35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year increase of 8041.0%. This contributed to the annual value of -$77.4 million for FY2024, which is 6475.8% up from last year.
  • Cartesian Therapeutics' EBITDA amounted to -$35.9 million in Q3 2025, which was down 4840.9% from $15.9 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' EBITDA registered a high of $28.7 million during Q1 2022, and its lowest value of -$177.6 million during Q4 2023.
  • Over the past 5 years, Cartesian Therapeutics' median EBITDA value was -$10.3 million (recorded in 2024), while the average stood at -$17.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 312884.91% in 2023, then surged by 22134.22% in 2024.
  • Cartesian Therapeutics' EBITDA (Quarter) stood at $12.2 million in 2021, then crashed by 52.05% to $5.9 million in 2022, then plummeted by 3128.85% to -$177.6 million in 2023, then surged by 94.22% to -$10.3 million in 2024, then crashed by 249.75% to -$35.9 million in 2025.
  • Its EBITDA stands at -$35.9 million for Q3 2025, versus $15.9 million for Q2 2025 and -$17.7 million for Q1 2025.